Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors

Article Oncology

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok et al.

Summary: The 6.5-year results of the CheckMate 067 trial demonstrate durable clinical benefits with nivolumab plus ipilimumab or nivolumab monotherapy compared to ipilimumab alone in patients with advanced melanoma.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Dermatology

Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma

Nadia C. W. Kamminga et al.

Summary: This study explores the experiences and needs of metastatic melanoma survivors in resuming life after immune checkpoint inhibitors (ICIs) treatment. The prognosis switch and uncertainty about the future often cause mixed feelings among survivors. They face various challenges in different life domains and need to find a new balance. In terms of survivorship care (SSC) needs, survivors emphasize the importance of tailored patient information, a single point of contact, and psychosocial support for themselves and their close relatives.

BRITISH JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

Jason J. Luke et al.

Summary: The study demonstrates that Pembrolizumab as adjuvant therapy significantly prolongs recurrence-free survival in patients with stage II melanoma, with manageable safety profile.

LANCET (2022)

添加到收藏夹

Article Oncology

Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

F. Stephen Hodi et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

J. Haanen et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls

A. H. Boekhout et al.

Summary: This study found that long-term advanced melanoma survivors generally have lower health-related quality of life, more physical symptoms, and financial challenges compared to matched controls. This data may contribute to the development of appropriate survivorship care.

ACTA ONCOLOGICA (2021)

添加到收藏夹

Review Oncology

Novel adjuvant options for cutaneous melanoma

F. Dimitriou et al.

Summary: This review discusses the latest clinical trial data, current treatment landscape, and future progress for the management of resected stage IIIB-IIID melanoma. Adjuvant therapy with immunotherapy or targeted therapy is recommended for improving recurrence-free survival in high-risk melanoma patients.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma

J. Randall Patrinely et al.

Summary: This multicenter cohort study found that chronic immune-related adverse events (irAEs) associated with anti-PD-1 therapy were more common than previously recognized, with a considerable proportion of patients developing chronic irAEs such as endocrinopathies and arthritis. Visceral organ-related irAEs had lower rates of becoming chronic, highlighting the importance of considering the risks of chronic irAEs in treatment decision-making.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis

Florentia Dimitriou et al.

Summary: This study investigated the impact of immune-related adverse events (irAEs) on the survival of advanced melanoma patients treated with immune-checkpoint inhibitors, finding that irAEs are correlated with treatment efficacy and may serve as potential prognostic markers in a non-adjuvant setting. Treatment with immunomodulatory agents did not affect the efficacy of immune checkpoint inhibitors, and patients with underlying autoimmune conditions may experience disease exacerbation.

CANCERS (2021)

添加到收藏夹

Article Oncology